Deans' stroke musings: Retina is a Marker for Cerebrovascular Heath

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, July 28, 2025

Retina is a Marker for Cerebrovascular Heath

Whomever wrote this didn't know that stroke has been called neurological disease by the WHO since 2006 not cerebrovascular, once again proving the stroke medical world doesn't keep up to date in their field!

Retina is a Marker for Cerebrovascular Heath

ClinicalTrials.gov ID NCT04753970

Sponsor:Mayo Clinic

Information Provided by:Michelle P Lin, MD, MPH

Study Start (Actual)2021-02-09

Primary Completion (Estimated) 2026-06

Study Completion (Estimated)2026-06

Enrollment (Estimated)100

Study Type: Interventional

Last Update Posted2025-07-23 Study Overview

Brief Summary

Cerebral small vessel disease (SVD), present in 80-94% of adults over age 65 years, increases the risk of stroke by 2-fold, and dementia by 2.3-fold. There is currently no treatment to slow SVD progression. This study aims to test whether impaired cerebral and retinal vasoreactivity may serve as biomarker for SVD progression, and to evaluate the safety and efficacy of cilostazol (antiplatelet agent with vasodilatory and anti-inflammatory properties) for the treatment of SVD.

ClinicalTrials.gov